Applied Therapeutics Inc (APLT) has provided an update.
Applied Therapeutics, Inc. has unveiled a presentation offering insights into its management strategies and future plans for engaging with analysts, investors, and other interested parties. Additionally, the company has shared promising interim results from the Phase 3 INSPIRE trial, which is assessing the efficacy of its drug AT-007 in treating SORD Deficiency. This information, although not filed under the Securities and Exchange Act of 1934, provides a significant update on the company’s progress and potential impact on the market.
See more data about APLT stock on TipRanks’ Stock Analysis page.
